Stockscreener 앱 받기
80.52
2.99%
-2.48
시간 외 거래:
80.52
전일 마감가:
$83.00
열려 있는:
$83
하루 거래량:
301.55K
Relative Volume:
0.84
시가총액:
$1.83B
수익:
$923.71M
순이익/손실:
$84.68M
주가수익비율:
20.43
EPS:
3.9419
순현금흐름:
$182.81M
1주 성능:
-1.62%
1개월 성능:
+3.22%
6개월 성능:
-2.22%
1년 성능:
+27.10%
1일 변동 폭
$79.98
$83.35
1주일 범위
$79.98
$83.66
52주 변동 폭
$62.60
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(609) 759-1810
주소
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
80.52 | 1.87B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock - Investing.com
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan - Stock Titan
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com India
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Director Jeanne Thoma receives 4,357-share grant at ANI Pharmaceuticals (ANIP) - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push - Yahoo Finance
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth - Yahoo Finance
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock - Investing.com UK
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock By Investing.com - Investing.com South Africa
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
[144] ANI PHARMACEUTICALS INC SEC Filing - Stock Titan
ANI Pharmaceuticals, Inc. $ANIP Stock Holdings Trimmed by Global Alpha Capital Management Ltd. - MarketBeat
ANIP (NASDAQ: ANIP) broker files Form 144 for 11,862-share sale - Stock Titan
How ANI’s Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Recall, Raised Guidance and Buybacks Could Mean For Shareholders - Sahm
ANI Pharmaceuticals Revenue Grows 20 Percent in Q1 2026 Financial Results - asatunews.co.id
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANI Pharmaceuticals Inc (ANIP) Stock Down 3.2% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program - MSN
ANI Pharmaceuticals (ANIP) Edges Higher: Approaching Key Resistance LevelsWeak Sell Signals - The Legal Advocate
ANI Pharmaceuticals (ANIP) expected to beat earnings estimates: Should you buy? - MSN
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Penn Capital Management Company LLC Increases Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals Holds Steady Near Support as Trading Volume EasesBreakout Confirmation - The Legal Advocate
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Precision Trading with Ani Pharmaceuticals Inc. (ANIP) Risk Zones - Stock Traders Daily
ANI Pharmaceuticals (ANIP) Q1 earnings: What to expect - MSN
ANI Pharmaceuticals (ANIP) Q1 2026 Earnings: Revenue Beat, Guidance, and Stock DropNews and Statistics - IndexBox
ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan - Stock Titan
Barclays Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem - Yahoo Finance
ANI Pharmaceuticals Q1 2026 earnings preview - MSN
Profitable Stocks: MYR Group & ANI Pharmaceuticals to Watch, B&G Foods to SellNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook - MSN
Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks - Barchart
How Raised 2026 Guidance And A New Buyback At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Yahoo Finance
ANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales Rise - Yahoo Finance
UBS Group AG Has $11.90 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook - TradingView
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Ani Pharmaceuticals Insider Sold Shares Worth $1,127,120, According to a Recent SEC Filing - Moomoo
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ani Pharmaceuticals Inc 주식 (ANIP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HAUGHEY THOMAS | Director |
Jun 08 '26 |
Sale |
80.88 |
2,000 |
161,760 |
38,878 |
| CAREY STEPHEN P. | SVP & CFO |
Jun 05 '26 |
Option Exercise |
49.51 |
3,312 |
163,977 |
183,705 |
| CAREY STEPHEN P. | SVP & CFO |
Jun 05 '26 |
Sale |
80.00 |
3,312 |
264,960 |
180,393 |
0.95%
1.13%
자본화:
|
볼륨(24시간):